Asphelia Announces Initiation of An Independent TSO Trial for Multiple Sclerosis
Monday April 7, 8:00 am ET
MADISON, Wis., April 7, 2008 (PRIME NEWSWIRE) -- As announced in the March 7th issue of the Wisconsin State Journal, Dr. John Fleming, a leading neurologist at the UW Hospital, is initiating an investigator-initiated IND clinical trial to assess the safety and efficacy of Trichuris suis ova (TSO) in the treatment of Multiple Sclerosis (MS). Dr. Fleming's trial is funded by the Multiple Sclerosis Society, and is the first of its kind within the United States.
About TSO: ASP1002 is a helminth ova (worm egg) technology currently being developed for the treatment of autoimmune diseases and immunological disorders, such as Crohn's Disease, Multiple Sclerosis, and asthma. More than 1,000 patients in Europe and the United States have taken TSO without significant side effects or safety issues.